Endo gets US approval for long-acting testosterone
Drugmaker Endo Pharmaceuticals announced Thursday that it received U.S. approval for its long-acting testosterone injection Aveed, which joins a crowded field of hormone-boosting drugs aimed at aging American men.
Trending on the Topix Network
Sat Mar 08, 2014
FDA Approves Injectable Testosterone Replacement Therapy, Aveed
The FDA has approved Aveed injection for the treatment of adult men with hypogonadism that is associated with a deficiency or absence of the male hormone testosterone.
Fri Mar 07, 2014
Ubs Ag Increases Endo Health Solutions Price Target to $90.00
The firm currently has a "buy" rating on the stock. UBS AG's price target suggests a potential upside of 22.02% from the stock's previous close.
Endo Health Solutions Price Target Raised to $87.00 at Citigroup Inc.
Citigroup Inc.'s price target suggests a potential upside of 17.95% from the company's current price.
Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific...
"We are thrilled that Sue has joined the Endo team as the progression of Endo to a leading specialty healthcare company continues," said , president and chief executive officer of Endo.
Thu Mar 06, 2014
The Miami Herald
Endo gets US approval for long-acting testosterone
Drugmaker Endo Pharmaceuticals says it received U.S. approval for its long-acting testosterone injection Aveed, which joins a crowded field of hormone-boosting drugs for men.
FDA approves locally made drug for low testosterone
The Food and Drug Administration on Thursday granted marketing approval to Aveed, an injectable testosterone replacement therapy developed by Endo Pharmaceuticals for men living with hypogonadism .
FDA Approves Endo U.S. Testosterone Replacement Therapy
Endo Pharmaceuticals has received FDA approval of AVEED injection for the treatment of adult men with hypogonadism that is associated with a deficiency or absence of the male hormone testosterone.
Wed Mar 05, 2014
BioDelivery Sciences to Present at the 26th Annual ROTH Conference
The presentation is scheduled for The New Drug Application for BUNAVAIL for the treatment of opioid dependence is currently under review by the U.S. Food and Drug Administration , and based on timelines established by the Prescription Drug User Fee Act , the review of the BUNAVAIL NDA is expected to be completed by Dr. Sirgo will be providing an ... (more)
Tue Mar 04, 2014
Endo Pharmaceuticals To Pay Connecticut In Court Resolution
The court case United States ex rel. Ryan v. Endo Pharmaceuticals has reached a settlement.
Mon Mar 03, 2014
Endo Health Solutions Price Target Raised to $85.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co.' s target price suggests a potential upside of 6.49% from the stock's previous close.
Five Star Equities Issues New Research Reports on CLNE, DRQ, ELGX and ...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Endo Reports Shareholder Approval of its Acquisition of Paladin Labs
The proposed transaction remains subject to certain conditions and approvals, including approval of the , listing of New Endo shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions.
Fri Feb 28, 2014
North Platte Bulletin
Settlement returns $144K to Nebraska
Attorney General Jon Bruning announced Friday than Nebraska joined a global settlement with Endo Pharmaceuticals, a subsidiary of pharmaceutical product manufacturer Endo Health Solutions , and the state will receive $144,453.
NC to receive $1.5 million from Endo Pharma settlement
Endo Pharmaceuticals has agreed to pay North Carolina $1.5 million as part of a $172.9 multi-state settlement over allegations that the company unlawfully marketed one of its drugs, Attorney General Roy Cooper's office announced Friday.
Endo Health Solutions Inc. Announces Departure Of Chief Scientific Officer
During Ivan's tenure with Endo he has been responsible for building a focused approach to drug development that ultimately led to multiple product approvals.
Endo Health -6% as loss widens on writedown, legal costs
Endo Health Solutions shares sink on widening Q4 losses after the drug maker warned of a significant writedown and high litigation expenses earlier this month.
Endo Completes Acquisition of Paladin Labs
Endo International plc , formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately .
BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference
The presentation is scheduled for BDSI submitted a New Drug Application for BUNAVAIL for the treatment of opioid dependence, and based on timelines established by the Prescription Drug User Fee Act , the review of the BUNAVAIL NDA is expected to be completed by Additionally, Dr. Sirgo will provide an update on the progress made by BDSI and its ... (more)
Wed Feb 26, 2014
Stocks: Observations on Goldman, Gulfport, Cisco, and Endo Health Solutions
You will receive a download link right in your email inbox for each of the free reports that you choose.